Abstract
The aim of our study was to determine a complex of risk factors of the perimenopausal melatonin deficiency syndrome (SPDM) in postmenopausal women and women during menopausal transition suffering from climacteric syndrome. The study involved 278 women. They were divided into two groups: I group included 246 menopausal women and II group included 32 women during the menopausal transition. The Medical History was collected, the menopausal index, and anthropometric measures were determined. The study was conducted with a help of the test questionnaire for melatonin deficiency (TQMD), the women’s health questionnaire (WHQ), and detection of the level of 6- sulfatoxymelatonin (6-SOMT) in urine. According to the obtained data, risk factors of SPDM in women during the menopausal transition are the chronological age increment, overweight, and the reduction of the estradiol level. The leading risk factors of SPDM in postmenopausal women are the chronological age increment, overweight with visceral type of obesity and changes in the hormonal profile. Thus, SPDM is a new clinical and laboratory marker of aging of the female reproductive system, an important screening tool for detecting the development of CC in women during the menopausal transition and menopausal women.
Highlights
Female aging is associated with a deficiency of sex steroids, reduction of level of the pineal gland hormone – melatonin (MT) plays an important role in this process
SPDM is a donosological state and it is a predecessor of a clinical form of the pathological climacteria development climacteric syndrome (CC)
This study shows that CC is formed in women, both at menopausal transition and at menopause affected by SPDM
Summary
Female aging is associated with a deficiency of sex steroids, reduction of level of the pineal gland hormone – melatonin (MT) plays an important role in this process. A new concept - perimenopausal melatonin deficiency syndrome (SPDM) is suggested. SPDM is a donosological state and it is a predecessor of a clinical form of the pathological climacteria development climacteric syndrome (CC). A screening tool, a test questionnaire for melatonin deficiency (TQMD) [2] is used for this purpose. The 6-SOMT level of urine is measured, and severity of symptoms according to the scales of the Women’s Health Questionnaire - a “disease specific” instrument - are evaluated [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
